Completed PHASE2 INTERVENTIONAL 2-arm NCT00972075

Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects

A Double-Blind, Placebo-Controlled Study of Circadin™ for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects

Sponsor: Neurim Pharmaceuticals Ltd.

Conditions Blindness Non-24 Hour Sleep-Wake Disorder

Interventions melatonin (Circadin) placebo

Updated 6 times since 2017 Last updated: Sep 6, 2009 Started: Feb 28, 2006 Primary completion: Aug 31, 2007 Completion: Oct 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Blindness and Non-24 Hour Sleep-Wake Disorder and is currently completed. Neurim Pharmaceuticals Ltd. leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Neurim Pharmaceuticals Ltd.

Data source: Neurim Pharmaceuticals Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Atlanta, United States
• New York, United States